



HHS Public Access

Author manuscript

J Am Geriatr Soc. Author manuscript; available in PMC 2023 December 01.

Published in final edited form as:

J Am Geriatr Soc. 2022 December ; 70(12): 3560–3569. doi:10.1111/jgs.18005.

Prolonged Use of Newly Prescribed Gabapentin After Surgery

Tasce Bongiovanni, MD, MPP¹, Siqi Gan, MPH², Emily Finlayson, MD¹, Joseph Ross, MD^{3,4,5}, James D. Harrison, MPH, PhD⁶, John Boscardin, PhD⁷, Michael A. Steinman, MD^{8,9}

¹University of California San Francisco School of Medicine, Department of Surgery, San Francisco, CA

²University of California San Francisco Pepper Center, San Francisco, CA

³Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut

⁴Section of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

⁵Department of Health Policy and Management, Yale University School of Public Health, New Haven, Connecticut

⁶Division of Hospital Medicine, University of California San Francisco School of Medicine, San Francisco, CA

⁷University of California San Francisco School of Medicine, Department of Medicine, San Francisco, CA

⁸Division of Geriatrics, University of California San Francisco School of Medicine

⁹San Francisco VA Medical Center, San Francisco, CA

Abstract

Background—Surgeons have made substantial efforts to decrease postoperative opioid prescribing, largely because it can lead to prolonged use. These efforts include adoption of non-opioid pain medication including gabapentin. Like opioids, gabapentin use may be prolonged, increasing the risk of altered mental status and even overdose and death when taken concurrently with opioids. However, little is known about postoperative prolonged use of gabapentin in older adults.

Corresponding Author: Tasce Bongiovanni, MD, 513 Parnassus Ave, HSW 1600, San Francisco, CA 94143-0790, Mobile: 707.853.1219, Office: 415.514.8934, @TasceB.

Author Contributions:

Tasce Bongiovanni, MD, MPP: study concept and design, acquisition of data, analysis and interpretation of data, and preparation of manuscript

Siqi Gan, MPH: analysis and interpretation of data, and preparation of manuscript

Emily Finlayson, MD: study concept and design, interpretation of data, and preparation of manuscript

Joseph Ross, MD: interpretation of data, and preparation of manuscript

James Harrison, PhD: interpretation of data, and preparation of manuscript

John Boscardin, PhD: study concept and design, acquisition of data, analysis and interpretation of data, and preparation of manuscript.

Michael Steinman, MD: study concept and design, acquisition of data, analysis and interpretation of data, and preparation of manuscript

Conflict of Interest:

The authors have no conflicts of interest. Dr Finlayson is co-founder of Ooney Inc.

Methods—We merged a 20% sample of Medicare Carrier, MedPAR and Outpatient Files with Part D for 2013-2018. We included patients >65 years old without prior gabapentinoid use who underwent common non-cataract surgical procedures. We defined new postoperative gabapentin as fills for 7 days before surgery until 7 days after discharge. We excluded patients whose discharge disposition was hospice or death. The primary outcome was prolonged use of gabapentin, defined as a fill >90 days after discharge. To identify risk factors for prolonged use we constructed logistic regression models, adjusted for procedure and patient characteristics, length of stay, disposition location and care complexity.

Results—Overall, 17,970 patients (3% of all eligible patients) had a *new* prescription for gabapentin after surgery. Of these, the mean age was 73 years-old and 62% were female. The most common procedures were total knee (45%) and total hip (21%) replacements. Prolonged use occurred in 22%. Those with prolonged use were more likely to be women (64% vs 61%), be non-white (14% vs 12%), have concurrent prolonged opioid use (44% vs 18%), and have undergone emergency surgery (8% vs 4%). On multivariable analysis, being female, having a higher Charlson comorbidity score, having an opioid prescription at discharge and at >90 days and having a higher care complexity were associated with prolonged use of gabapentin.

Conclusions—More than one-fifth of older adults prescribed gabapentin postoperatively filled a prescription >90 days after discharge, especially among patients with more comorbidities and concurrent prolonged opioid use, increasing the risk of adverse drug events and polypharmacy.

Keywords

pain control; postoperative care; deprescribing; older adults (3-5)

Introduction

In a recent nationwide shift, surgeons have sought to decrease postoperative opioid prescribing by adopting the use of non-opioid ‘multimodal’ pain regimens.¹⁻⁴ Gabapentinoids (gabapentin and pregabalin) are now commonly administered during the postoperative period for many surgical patients, especially with the rise in adoption of ‘enhanced recovery after surgery’ pathways.⁴ Multimodal pain medication use, including that of gabapentin, has tripled in the U.S. over the past decade.⁵ Studies indicate that a single preoperative dose of a gabapentinoid is associated with a decrease in postoperative pain and opioid consumption at 24 hours.⁶ However, gabapentinoids also increase postoperative sedation and dizziness in both the short and long-term.^{7,8}

In older adults (age ≥ 65), who account for almost half of all surgical patients each year in the US,⁹ gabapentinoids are often poorly tolerated because of pharmacokinetic and pharmacodynamic changes associated with aging, comorbidities, and interactions with other medications.¹⁰ In fact, gabapentinoids are included in the AGS Beers Criteria list, explicitly detailing potentially inappropriate medications (PIMs) for older adults. There are strong recommendations to avoid using with opioids, due to risk of overdose, respiratory depression and death, except when transitioning from one to the other,^{11,12} and to dose reduce in older adults with poor kidney function.¹¹ The use of PIMs has been associated with adverse drug reactions and increased mortality across a wide variety of surgical procedures.^{13,14}

Nevertheless, older age is one of several risk factors for receiving more opioids and multimodal pain medication in the postoperative period.^{5,15} While short-term use has all of these inherent risks, much like opioids, gabapentin can be continued long-term with the risk of altered mental status, dizziness, and drowsiness.^{11,16} Prolonged use also has its own unique hazards by contributing to polypharmacy, shown to increase adverse events and hospitalizations.^{17,18}

The shift towards multimodal pain regimens, including gabapentin, has taken place without attention to ensuring that they, like opioids, are appropriately discontinued soon after surgery. The prevalence of prolonged use of post-operative gabapentin among older adults is unknown, as are the factors associated with prolonged use. Finally, the incidence of prolonged use in conjunction with opioids, a combination found to lead to serious adverse events including overdose and death,^{11,12} has not been studied. Therefore, we sought to describe prolonged use of postoperatively prescribed gabapentin and characterize the associated patient and medication-related factors.

Methods

Data Source

We used the 20% Medicare sample for years 2013-2018. Medicare is a federal health insurance program which covers approximately 97% of all US citizens ≥ 65 ¹⁹ and the dataset is a 20% representative sample. We merged Medicare Carrier, MedPAR and Outpatient Files with Part D files and used the Master Beneficiary Summary File (MBSF) base file, the chronic conditions segment, the other chronic or potentially disabling conditions segment, and the National Death Index segment to determine cohort composition regarding age, gender, race and comorbidity score, identify hospitalizations and fee-for service claims at free-standing ambulatory surgical centers for specifically identified procedures, discharge location and identify prescription fills. The study was approved by the University of California San Francisco Institutional Review Board.

Study Population

We included patients ≥ 66 years at time of the procedure undergoing one of the 14 most common non-cataract surgeries performed in older adults,^{20,21} (Supplementary Appendix 1) who had at least one prescription filled in the system 3 months prior to surgery. To ensure we had patients who were using their Part D benefit, we only included patients with continuous Part D coverage for 3 months before and 6 months after the procedure date. For patients who had multiple procedures over the time period, we considered only their first procedure date. We excluded patients whose discharge disposition was death or hospice,²² who died within 30 days after discharge and patients who had ≥ 3 procedures on the same day. We excluded new pregabalin prescriptions from the analysis as these were only 0.34% of our original cohort and may represent important differences in prescribing habits.

We included patients ≥ 66 years to allow for one year prior to the procedure to compile comorbidities to calculate a Charlson comorbidity score²³ using an updated 17 disease version more appropriate for use in administrative databases.²⁴ The 14 surgical procedures

included represent a wide range of surgical risk, anatomic regions and surgical specialties. We defined outpatient procedures using HCPCS/CPT codes, and inpatient procedures using ICD9-CM or ICD10-PCS codes (Supplementary Appendix2). We included specific groups of patients who had two different procedures on the same day if those procedures both fell into our inclusion criteria (specifically Total Shoulder Arthroplasty/Total Knee Arthroplasty and Total Shoulder Arthroplasty/Total Hip Arthroplasty) and we combined the spinal procedures (laminectomy and laminotomy) into one category for analysis given their extensive overlap.

From this cohort (Supplementary Appendix3), we analyzed patients who had a *new* discharge prescription for gabapentin at the time of surgery. We considered a discharge prescription as any fill between 7 days before and 7 days after the surgery (or discharge for inpatients), as some surgical practices prescribe medications preoperatively. We defined a *new* fill of a gabapentin if the medication had not been prescribed in the 3 months prior to surgery.²⁰ We pulled the NDC codes from Part D claims and then linked them with Medispan crosswalk files to identify generic drug names and prescription information including dosage information.

Outcomes and Data Analyses

The primary outcome is prolonged use of gabapentin in the postoperative period, defined as a prescription refilled at 90-180 days after discharge from surgery, a time period based on definitions of prolonged use of opioids after surgical procedures.^{20,25,26} We calculated the days' supply and average daily dose. We defined which procedures most commonly had gabapentin prescribed postoperatively, and the unadjusted risk of prolonged use for each medication category and for type of surgery. Additionally, we assessed concomitant prolonged use of opioids since that can increase the risk of adverse drug events (Supplementary Appendix4).

To identify risk factors for prolonged use we constructed logistic regression models, adjusted for procedure characteristics (surgery type), patient characteristics (age, sex, race/ethnicity, Charlson comorbidity score), length of stay, disposition location and care complexity^{17,27,28} (number of physicians seen in prior 6 months). We handled competing risks through a descriptive model as the number of deaths within 30 days were too small for a Fine-Grey calculation.

Results

Patient Demographics

Of 604,356 older adults meeting inclusion criteria (Supplementary Appendix 2), 17,481 (3%) of patients had a *new* prescription for gabapentin after the index procedure and were included in our final cohort (Table 1). Of these, the mean age was 73 years old, 62% were women and 85% were white. The median Charlson comorbidity score was 1 (q1, q3; 0, 2) and the marker of care complexity, the average number of physicians seen in the prior 6 months was a median of 13 (q1, q3; 2, 17). The average length of stay was 2.9 days (sd 4.6 days). Most patients were discharged home (94%) with 41% being discharged with

home health. Surgery was planned in 94% of the cohort. Seventy-three percent of patients were also discharged with an opioid prescription, and at 90 days, 24% were still receiving an opioid. The most common two procedures with gabapentin prescribed at discharge were total knee (43%) and total hip (20%) replacements (Table 2).

Among patients with new prescriptions, 23% (n=4,031) continued to receive gabapentin prescriptions at 90+ days after surgery. Those with prolonged use were more likely to be women (24% vs 21%), be non-white (24% vs 23%) and have undergone emergency surgery (38% vs 22%). (Table 1). While only 20% of those with prolonged use had an opioid prescription at discharge (compared to 81% without prolonged use), this number rose to 41% for prolonged concomitant opioid use. The procedures with the highest proportion of prolonged use were carotid endarterectomy (64%) and laparoscopic cholecystectomy (53%). Another 5 categories of procedures had prolonged use rates in the 40-50% range including: lumbar laminotomy/laminectomy, open ventral hernia repair, open inguinal hernia repair, laparoscopic prostatectomy and laparoscopic hysterectomy (Table 2).

Associations with Prolonged Use

The univariate analysis identified multiple variables associated with prolonged use of gabapentin including older age, female sex, non-white race, higher Charlson comorbidity score, concomitant opioid use at 90 days, a procedure performed in-hospital, non-home discharge, higher care complexity and emergency surgery as risk factors for prolonged use of gabapentin (Supplementary Appendix5). The days supply at discharge was not associated with prolonged use, however variation was high between surgical populations and in some procedures those with prolonged use were discharged with more days' supply compared to those without prolonged use (Figure 1). The procedures most associated with prolonged use of gabapentin were carotid endarterectomy, laparoscopic cholecystectomy and open inguinal hernia repair.

On multivariable logistic regression, we found that female sex, higher Charlson comorbidity score, concomitant opioid use at 90 days, and emergency surgery were associated with prolonged use (Table 3). Discharge to SNF was also associated with prolonged use on multivariable analysis, however this population represented only 5% of the overall cohort. The same procedures remained with the highest odds of prolonged gabapentin use in multivariable regression.

Competing Risks

We handled competing risks descriptively. Among 604,356 patients who were hospitalized and survived thru discharge, 17,481 filled a prescription for gabapentin at discharge. Among those, 0 had died by 90 days and 17,970 were alive at 90 days and still Part D.

Discussion

In this study, we investigated the incidence of and associations with prolonged use of gabapentin in the postoperative period. We found that prolonged use of gabapentin is high in older adults in the postoperative period with over one fifth of older adults in our cohort having prolonged use. Although prescribing was relatively infrequent, once the medication

was started it was likely to be continued. This is especially concerning given it was most likely to be continued in populations at highest risk for adverse events, such as those with a higher Charlson comorbidity score and those who underwent emergency surgery. While the procedures at highest odds for prolonged use represent a small portion of the overall population of procedures for which gabapentin is prescribed they represent procedures that may be more likely done in the emergent setting (carotid endarterectomy, laparoscopic cholecystectomy, as examples). These patients may greatly benefit from interventions that clearly prescribe pain medication for short-term use and increase communication between surgeon and PCP. While sex and race had statistically significant associations with prolonged use, the percentage differences were small between these groups and may not be clinically significant. However, we show that prolonged use of gabapentin is associated with prolonged use of opioids, especially dangerous since concomitant use of gabapentin and opioids has been found to increase the risk of opioid related overdose and death.^{11,12,29}

Concerningly, our study has similar findings to many studying prolonged use of opioids. Like opioids, we found that once started, the continuation of gabapentin is relatively common. While gabapentin has some misuse potential, there are other reasons that gabapentin may be continued in the postoperative period. Transitions of care, such as discharge after a surgical procedure, are associated with medication errors or discrepancies,³⁰ and 19-23% of patients suffer an adverse event, most commonly an adverse drug event.³⁰ Prolonged use can also occur due to patients' poor understanding of medications³¹ or guidance on how long to continue medications,³² as well as lack of clinician awareness, including poor insight into why medications were originally prescribed, lack of guidelines, fear of making a change, work practice of prescribing without review, and a culture of prescribing more as opposed to reviewing lists and stopping unnecessary medications.³¹ This may be especially acute in surgical procedures that aren't usually known to have neurologic pain, so physicians don't associate the prescription as short-term use connected to the surgery. Currently, little is known about why patients have prolonged use, however, this and concomitant opioid use is dangerous, especially in older adults due to the sedating effects and risk of respiratory depression.^{11,12,29} Finally, the use of gabapentin has been touted as a vehicle to decrease opioid use. However, in our study, the two were often used together.

Our study has several limitations. Specific procedures, even some which were associated with prolonged use, were too small of a subgroup to meaningfully interpret the results. Additionally, some patients may have received a short supply of medications from the hospital pharmacy which will not be captured in Part D data. We excluded patients with Medicare Advantage as they may not necessarily use Part D to fill medication prescriptions, which may limit our generalizability to fee-for-service beneficiaries. However, our sample size remains large despite this exclusion to allow to make robust assessments of the non-Medicare Advantage population. Finally, our ability to detect differences between racial/ethnic groups is limited by the manner in which Medicare traditionally categorized patients and has low validity in some groups.³³

In summary, we have shown for the first time that older adults discharged with a prescription for gabapentin are likely to have prolonged use of the medication, especially if they have

more comorbid conditions, and that these patients also continue opioids. These findings suggest that broad-based shifts in pain management to avoid opioid prescribing has potential long-term effects and that close attention needs to be paid to medications meant to be used short-term in the post-surgical discharge period. While gabapentin may have some benefit in the short-term and some older adults may have persistent pain that warrants prolonged use of gabapentin, particularly after spinal surgery, we speculate that a large proportion of this prolonged use is not intentional, and that the system needs to be improved to prevent both polypharmacy and unintentional continuation. This is especially evident in the fact that the non-orthopedic procedures are at higher odds of having prolonged use, suggesting that this prolonged use may be unintentional and therefore an area important to intervene upon. As non-opioid medications are increasingly used after surgery, careful attention needs to be paid to ensuring that these medications are in fact substituting for opioids and are appropriately discontinued.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Disclosures:

Dr. Bongiovanni was funded by the Agency for Healthcare Research and Quality (AHRQ) (K12HS026383), National Institutes of Health (NIH) through the National Institute on Aging (K23AG073523) and the Robert Wood Johnson Foundation (RWJF) Harold Amos Medical Faculty Development Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality, NIH nor RWJF.

Dr. Harrison is supported by the National Institute Of Aging of the National Institutes of Health under Award Number K01AG073533 and the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR001870. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International; in addition, Dr. Ross is an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc.

Dr. Steinman was funded by the National Institutes of Health (K24AG049057, R24AG064025, and P30AG044281).

Dr Finlayson is supported by the National Institute of Health (R01AG058616 and R01AG067507). She is co-founder of Ooney Inc.

Sponsor's Role

The sponsor had no role in the design, methods, subject recruitment, data collections, analysis or preparation of the paper.

References

1. Bongiovanni T, Lancaster E, Ledesma Y, et al. Systematic Review and Meta-Analysis of the Association Between Non-Steroidal Anti-Inflammatory Drugs and Operative Bleeding in

the Perioperative Period. *J Am Coll Surg*. Published online January 27, 2021. doi:10.1016/j.jamcollsurg.2021.01.005

2. Lancaster E, Bongiovanni T, Lin J, Croci R, Wick E, Hirose K. Residents as Key Effectors of Change in Improving Opioid Prescribing Behavior. *J Surg Educ*. 2019;76(6):e167–e172. doi:10.1016/j.j Surg.2019.05.016 [PubMed: 31155453]
3. Bongiovanni T, Hansen K, Lancaster E, O'Sullivan P, Hirose K, Wick E. Adopting best practices in post-operative analgesia prescribing in a safety-net hospital: Residents as a conduit to change. *Am J Surg*. 2020;219(2):299–303. doi:10.1016/j.amjsurg.2019.12.023 [PubMed: 31928779]
4. Wick EC, Grant MC, Wu CL. Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and Techniques: A Review. *JAMA Surg*. 2017;152(7):691. doi:10.1001/jamasurg.2017.0898 [PubMed: 28564673]
5. Johansen ME. Gabapentinoid Use in the United States 2002 Through 2015. *JAMA Intern Med*. 2018;178(2):292–294. doi:10.1001/jamainternmed.2017.7856 [PubMed: 29297045]
6. Grover VK, Mathew PJ, Yaddanapudi S, Sehgal S. A single dose of preoperative gabapentin for pain reduction and requirement of morphine after total mastectomy and axillary dissection: randomized placebo-controlled double-blind trial. *J Postgrad Med*. 2009;55(4):257–260. doi:10.4103/0022-3859.58928 [PubMed: 20083871]
7. Hurley RW, Cohen SP, Williams KA, Rowlingson AJ, Wu CL. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis. *Reg Anesth Pain Med*. 2006;31(3):237–247. doi:10.1016/j.rapm.2006.01.005 [PubMed: 16701190]
8. Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. *Br J Anaesth*. 2015;114(1):10–31. doi:10.1093/bja/aeu293 [PubMed: 25209095]
9. Berian JR, Rosenthal RA, Baker TL, et al. Hospital Standards to Promote Optimal Surgical Care of the Older Adult. *Ann Surg*. 2018;267(2):280–290. doi:10.1097/SLA.0000000000002185 [PubMed: 28277408]
10. McKeown JL. Pain Management Issues for the Geriatric Surgical Patient. *Anesthesiol Clin*. 2015;33(3):563–576. doi:10.1016/j.anclin.2015.05.010 [PubMed: 26315638]
11. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults: 2019 AGS BEERS CRITERIA® UPDATE EXPERT PANEL. *J Am Geriatr Soc*. 2019;67(4):674–694. doi:10.1111/jgs.15767 [PubMed: 30693946]
12. Bykov K, Bateman BT, Franklin JM, Vine SM, Paterno E. Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. *JAMA Netw Open*. 2020;3(12):e2031647. doi:10.1001/jamanetworkopen.2020.31647 [PubMed: 33372975]
13. Iaboni A, Rawson K, Burkett C, Lenze EJ, Flint AJ. Potentially Inappropriate Medications and the Time to Full Functional Recovery After Hip Fracture. *Drugs Aging*. 2017;34(9):723–728. doi:10.1007/s40266-017-0482-6 [PubMed: 28776209]
14. Finlayson E, Maselli J, Steinman MA, Rothberg MB, Lindenauer PK, Auerbach AD. Inappropriate medication use in older adults undergoing surgery: a national study. *J Am Geriatr Soc*. 2011;59(11):2139–2144. doi:10.1111/j.1532-5415.2011.03567.x [PubMed: 21883113]
15. Soprano SE, Hennessy S, Bilker WB, Leonard CE. Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016. *JAMA Netw Open*. 2020;3(6):e207664–e207664. doi:10.1001/jamanetworkopen.2020.7664 [PubMed: 32579193]
16. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. *J Am Soc Nephrol JASN*. 2018;29(7):1970–1978. doi:10.1681/ASN.2018010096 [PubMed: 29871945]
17. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and Prescribing Quality in Older People. *J Am Geriatr Soc*. 2006;54(10):1516–1523. doi:10.1111/j.1532-5415.2006.00889.x [PubMed: 17038068]
18. Steinman MA. Polypharmacy and the balance of medication benefits and risks. *Am J Geriatr Pharmacother*. 2007;5(4):314–316. doi:10.1016/j.amjopharm.2007.12.009 [PubMed: 18179988]
19. Moon M What Medicare Has Meant To Older Americans. :16.

20. Thiels CA, Habermann EB, Hooten WM, Jeffery MM. Chronic use of tramadol after acute pain episode: cohort study. *BMJ*. 2019;365. doi:10.1136/bmj.11849
21. Deiner S, Westlake B, Dutton RP. Patterns of Surgical Care and Complications in Elderly Adults. *J Am Geriatr Soc*. 2014;62(5):829–835. doi:10.1111/jgs.12794 [PubMed: 24731176]
22. Zhu Y, Stearns SC. Post-Acute Care Locations: Hospital Discharge Destination Reports vs Medicare Claims. *J Am Geriatr Soc*. 2020;68(4):847–851. doi:10.1111/jgs.16308 [PubMed: 31880309]
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8 [PubMed: 3558716]
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol*. 1992;45(6):613–619. doi:10.1016/0895-4356(92)90133-8 [PubMed: 1607900]
25. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. *JAMA Surg*. 2017;152(6):e170504–e170504. doi:10.1001/jamasurg.2017.0504 [PubMed: 28403427]
26. Harbaugh CM, Nalliah RP, Hu HM, Englesbe MJ, Waljee JF, Brummett CM. Persistent Opioid Use After Wisdom Tooth Extraction. *JAMA*. 2018;320(5):504. doi:10.1001/jama.2018.9023 [PubMed: 30088000]
27. Steinman MA, Hanlon JT. Managing Medications in Clinically Complex Elders: “There’s Got to Be a Happy Medium.” *JAMA*. 2010;304(14):1592–1601. doi:10.1001/jama.2010.1482 [PubMed: 20940385]
28. Roth MT, Ivey JL, Esserman DA, Crisp G, Kurz J, Weinberger M. Individualized Medication Assessment and Planning: Optimizing Medication Use in Older Adults in the Primary Care Setting. *Pharmacother J Hum Pharmacol Drug Ther*. 2013;33(8):787–797. doi:10.1002/phar.1274
29. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. *PLoS Med*. 2017;14(10):e1002396. doi:10.1371/journal.pmed.1002396 [PubMed: 28972983]
30. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Promoting effective transitions of care at hospital discharge: A review of key issues for hospitalists. *J Hosp Med*. 2007;2(5):314–323. doi:10.1002/jhm.228 [PubMed: 17935242]
31. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. *BMJ Open*. 2014;4(12):e006544. doi:10.1136/bmjopen-2014-006544
32. Bremner Samantha Ms, Webster Fiona P, Katz Joel P, Watt-Watson Judy P, McCartney Colin Mbc. Older adults’ postoperative pain medication usage after total knee arthroplasty: A qualitative descriptive study. *J Opioid Manag*. 2012;8(3):145–152. doi:10.5055/jom.2012.0110 [PubMed: 22798174]
33. Jarrín OF, Nyandeghe AN, Grafova IB, Dong X, Lin H. Validity of Race and Ethnicity Codes in Medicare Administrative Data Compared With Gold-standard Self-reported Race Collected During Routine Home Health Care Visits. *Med Care*. 2020;58(1):e1. doi:10.1097/MLR.0000000000001216 [PubMed: 31688554]

Key Points:

Prolonged use of medications for older adults can lead to adverse events and polypharmacy yet is relatively common among older surgical patients who receive a gabapentin prescription at discharge.

Gabapentin is most commonly prescribed in patients going orthopedic or spine surgeries.

Patients undergoing surgery are more likely to have prolonged use of gabapentin if they are women, have increased comorbidities, increased care complexity or who are prescribed opioids at discharge.

Why does this matter?

Prolonged use contributes to polypharmacy in an already at-risk population. As non-opioid medications are increasingly used in the surgical patient population, careful attention needs to be paid to ensuring that these medications are in fact substituting for opioids as opposed to be given together and that the medications are then appropriately discontinued. These findings suggest that broad-based shifts in pain management to avoid opioid prescribing has potential long-term effects and that close attention needs to be paid to medications meant to be used short-term in the post-surgical discharge period, especially those that are potentially inappropriate medications.




Figure 1:
Total Days Supply of Discharge Gabapentin Prescription for No prolonged Use versus Prolonged Use groups for each surgical procedure. (Median and IQR)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1:

Overall Cohort for New Gabapentin prescription, prolonged vs no prolonged use

	New gabapentin prescription (N=17,481, col%)	Prolonged use (N=4,031, row%)	No prolonged use (N=13,450, row%)	p-value
Age, mean (sd)	73.0 (5.4)	73.4 (5.7)	72.9 (5.4)	<0.001 ^a
Gender				<0.001 ^b
Female	10750 (61.5%)	2602 (24.2%)	8148 (75.8%)	
Male	6731 (38.6%)	1429 (21.2%)	5302 (78.8%)	
Race				0.01 ^b
White	14931 (85.4%)	3421 (22.9%)	11510 (77.1%)	
Black	965 (5.5%)	241 (25%)	724 (75%)	
Hispanic	859 (4.9%)	226 (26.3%)	633 (73.7%)	
Other	726 (4.2%)	143 (19.7%)	583 (80.3%)	
Race (White/Non-white)				0.26 ^b
White	14931 (85.4%)	3421 (22.9%)	11510 (77.1%)	
Non-white	2550 (14.6%)	610 (23.9%)	1940 (76.1%)	
Charlson Comorbidity Score median (q1, q3)	1 (0, 2)	1 (0, 4)	1 (0, 2)	<0.001 ^b
0	8119 (46.4%)	1580 (19.5%)	6539 (80.5%)	
1-2	5112 (29.2%)	1075 (21%)	4037 (79%)	
3-4	2350 (13.4%)	652 (27.7%)	1698 (72.3%)	
5+	1900(10.9%)	724 (38.1%)	1176 (61.9%)	
Gabapentin days supply	mean (sd), median (q1, q3)			
+/- 7 days around discharge	31.0 (24.6) 30 (14, 30)	50.5 (32.3) 30 (30, 90)	25.1 (18.0) 30 (14, 30)	<0.001 ^a
8-89 days after discharge	56.7 (33.5) 60 (30, 90)	68.5 (31.1) 60 (30, 90)	45.4 (30.7) 30 (30, 60)	<0.001 ^a
90-180 days after discharge	76.4 (37.5) 90 (45, 90)	76.4 (37.5) 90 (45, 90)	N/A	
Concurrent medication use (opioid use)				
Prescription +/- 7 days around discharge	12804 (73.3%)	2500 (19.5%)	10304 (80.5%)	<0.001 ^b
90-180 days after discharge	4246 (24.3%)	1750 (41.2%)	2496 (58.8%)	<0.001 ^b
Facility type				<0.001 ^b
Inpatient	14224 (81.4%)	2922 (20.5%)	11302 (79.5%)	
Outpatient	3257 (18.6%)	1109 (34%)	2148 (66%)	
LOS (Inpatient only) mean (sd) median (q1, q3)	2.9 (4.6) 2 (1, 3)	4.4 (7.5) 3 (2, 4)	2.6 (3.4) 2 (1, 3)	<0.001 ^a
Surgery planned				<0.001 ^b
Yes	16407 (93.9%)	3619 (22.1%)	12788 (77.9%)	

	New gabapentin prescription	Prolonged use	No prolonged use	p-value
	(N=17,481, col%)	(N=4,031, row%)	(N=13,450, row%)	
No	1074 (6.1%)	412 (38.4%)	662 (61.6%)	
Care complexity, median (q1, q3)				<0.001 ^b
q1 (1-2)	4837 (27.7%)	1077 (22.3%)	3760 (77.7%)	
q2 (3-12)	3472 (19.9%)	658 (19%)	2814 (81%)	
q3 (13-18)	5274 (30.2%)	1119 (21.2%)	4155 (78.8%)	
q4 (19 or more)	3898 (22.3%)	1177 (30.2%)	2721 (69.8%)	

* Care complexity: (number of physicians seen in prior 6 months).

sd = standard deviation. q = quartile. LOS = length of stay.

^a t-test;

^b chi-square test

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2:

Cohort by Procedure Type for New Gabapentin prescription, prolonged vs no prolonged use

	New gabapentin prescription (N=17,481, col%)	With gabapentin prolonged use (N=4,031, row%)	No gabapentin prolonged use (N=13,450, row%)	p-value
Type of procedure				<0.001 ^a
Total Knee Arthroplasty	7432 (42.5%)	1305 (17.6%)	6127 (82.4%)	
Total Hip Arthroplasty	3509 (20.1%)	556 (15.8%)	2953 (84.2%)	
Total Shoulder Arthroplasty/Total Knee Arthroplasty	2191 (12.5%)	896 (40.9%)	1295 (59.1%)	
Lumbar Laminotomy/Lumbar Laminectomy	1591 (9.1%)	340 (21.4%)	1251 (78.6%)	
Cholecystectomy, Laparoscopic	808 (4.6%)	131 (16.2%)	677 (83.8%)	
Initial Inguinal Hernia Repair, Open	557 (3.2%)	164 (29.4%)	393 (70.6%)	
Total Shoulder Arthroplasty /Total Hip Arthroplasty	341 (2.0%)	179 (52.5%)	162 (47.5%)	
Carotid Endarterectomy	298 (1.7%)	125 (41.9%)	173 (58.1%)	
Ventral Hernia Repair, Open	207 (1.2%)	133 (64.3%)	74 (35.7%)	
Total Shoulder Arthroplasty	165 (0.9%)	76 (46.1%)	89 (53.9%)	
Initial Inguinal Hernia Repair, Laparoscopic	146 (0.8%)	31 (21.2%)	115 (78.8%)	
Hysterectomy	99 (0.6%)	40 (40.4%)	59 (59.6%)	
Prostatectomy, Laparoscopic	76 (0.4%)	29 (38.2%)	47 (61.8%)	
Low Anterior Resection, Laparoscopic	61 (0.4%)	26 (42.6%)	35 (57.4%)	

NR = not reported as values are too small,

^a = chi-square test

Table 3:

Multivariable analysis for prolonged use of gabapentin

	Adjusted OR (95% CI)	p-value
Age	1.00 (1.00, 1.01)	0.59
Gender		<0.001
Male	ref.	
Female	1.26 (1.16, 1.36)	
Race		0.10
White	ref.	
Non-white	0.91 (0.82, 1.02)	
Charlson Comorbidity Score		<0.001
0	ref.	
1-2	1.09 (0.98, 1.22)	
3-4	1.39 (1.22, 1.60)	
5+	1.76 (1.52, 2.03)	
Concurrent medication use (opioid use)		<0.001
+/- 7 days around discharge		
No	ref.	
Yes	0.61 (0.56, 0.66)	<0.001
90-180 days after discharge		
No	ref.	
Yes	3.10 (2.86, 3.36)	0.05
Facility type		
Inpatient	ref.	
Outpatient	1.15 (1.00, 1.31)	<0.001
Disposition location		
Home	ref.	
Home under care of organized home health service organization	0.93 (0.85, 1.03)	
Transfer to acute care	1.74 (0.82, 3.70)	
Skilled nursing Facility	1.80 (1.56, 2.08)	
Other	0.28 (0.06, 1.30)	
Surgery planned		<0.001
Yes	ref.	
No	1.38 (1.19, 1.60)	
Care complexity (number of physicians seen in prior 6 months)		<0.001
q1 (1-2)	ref.	
q2 (3-12)	0.69 (0.61, 0.79)	
q3 (13-18)	0.72 (0.63, 0.82)	
q4 (19 or more)	0.79 (0.69, 0.91)	
Type of procedure		<0.001

	Adjusted OR (95% CI)	p-value
Total Knee Arthroplasty	ref.	
Total Hip Arthroplasty	0.85 (0.76, 0.96)	
Total Shoulder Arthroplasty/Total Knee Arthroplasty	2.49 (2.19, 2.84)	
Lumbar Laminotomy/Lumbar Laminectomy	1.14 (0.99, 1.32)	
Cholecystectomy, Laparoscopic	0.80 (0.65, 0.98)	
Initial Inguinal Hernia Repair, Open	1.51 (1.22, 1.88)	
Total Shoulder Arthroplasty/Total Hip Arthroplasty	3.37 (2.62, 4.33)	
Carotid Endarterectomy	2.20 (1.70, 2.85)	
Ventral Hernia Repair, Open	5.59 (4.11, 7.61)	
Total Shoulder Arthroplasty	3.67 (2.61, 5.18)	
Initial Inguinal Hernia Repair, Laparoscopic	1.00 (0.66, 1.53)	
Hysterectomy	2.15 (1.40, 3.32)	
Prostatectomy, Laparoscopic	2.67 (1.62, 4.39)	
Low Anterior Resection, Laparoscopic	2.79 (1.63, 4.78)	

OR: Odds Ratio, CI: Confidence Interval, ref: Reference group, q: Quartile